---
title: "Hugh S. Griffith Discloses Investment at NuCana plc with 12.0% Stake"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279683630.md"
description: "Hugh S. Griffith, CEO of NuCana plc, disclosed a 12.0% stake in the company, as noted in a Schedule 13D filed on March 18, 2026. His ownership surpassed 5% on June 20, 2025, and includes stock options exercisable within 60 days. Griffith states he holds shares for investment purposes and has no current plans for corporate changes, though he may review his position in the future. He has been leading NuCana since 2008, focusing on cancer treatment development."
datetime: "2026-03-18T22:46:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279683630.md)
  - [en](https://longbridge.com/en/news/279683630.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279683630.md)
---

# Hugh S. Griffith Discloses Investment at NuCana plc with 12.0% Stake

Hugh S. Griffith, the chief executive of NuCana plc, disclosed a 12.0% beneficial stake in NuCana plc. He filed a Schedule 13D on Mar. 18, 2026, noting his ownership first crossed the 5% threshold on June 20, 2025. The stake includes a large block of stock options exercisable within 60 days, signaling significant potential influence.

**Investor Intent**

Griffith says he holds NuCana shares "for investment purposes" and in the ordinary course. As CEO and a director, he "may have influence over the corporate activities" of the company, but this filing does not announce any deal, board change, or strategic shift.

He also states he "does not have any current plans or proposals" for actions like mergers, asset sales, or governance changes. He may review his position and change his plans over time.

**Investor's Background**

Hugh S. Griffith is the co-founder, chief executive officer, and a director of NuCana plc, a biotech company based in Edinburgh, United Kingdom. He has led the company since 2008, focusing on developing cancer treatments. As an operator-investor, he holds meaningful equity and options tied to his long-term leadership of the business.

Original SEC Filing: NuCana plc \[ NCNA \] - SCHEDULE 13D - Mar. 18, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [NCNA.US](https://longbridge.com/en/quote/NCNA.US.md)

## Related News & Research

- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Dyadic International Q1 net loss narrows](https://longbridge.com/en/news/286311192.md)
- [Alkermes reports encouraging data from Phase III study of Lumryz](https://longbridge.com/en/news/286349759.md)
- [Precigen Q1 revenue beats estimates on PAPZIMEOS launch](https://longbridge.com/en/news/286311056.md)